T All clinical trials

Explore recruiting t all clinical trials.

Recruiting t all studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

T All trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

Germany, France, Czechia, Netherlands, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety and efficacy of hCD1a-CAR T (OC-1) therapy, in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)_CARxALL

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children – sub protocol B

Netherlands, Spain, Norway, Sweden, Denmark, Germany +5 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol D

Netherlands, Denmark, Finland, Germany, Italy, Spain +5 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol C

Denmark, Norway, Italy, Netherlands, Finland, Spain +5 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated with OC-1 cells.

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

T All trials by city

T All in Toronto T All in Vancouver T All in Montreal T All in Calgary T All in Edmonton T All in Ottawa T All in Winnipeg T All in Quebec City T All in Hamilton T All in Kitchener T All in London T All in Halifax T All in New York T All in Los Angeles T All in Chicago T All in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease